1
PD-L1 ImagiNg to prediCt Durvalumab Treatment Response in HNSCC
Condition(s):Head and Neck CancerLast Updated:October 25, 2019Recruiting
Durvalumab: 496 Clinical Trials, Page 1 of 50
Hide Studies Not Open or Pending
2
Durvalumab and Tremelimumab for Pediatric Malignancies
Condition(s):Pediatric Cancer; Solid Tumor Pediatric; Hematological MalignanciesLast Updated:August 20, 2020Recruiting
3
Chemoradiation Followed by Durvalumab in Poor Risk and/or Elderly Patients With Stage III NSCLC
Condition(s):Stage III Non-small-cell Lung CancerLast Updated:June 22, 2020Not yet recruiting
4
Efficacy of Durvalumab in Non-muscle-invasive Bladder Cancer
Condition(s):Bladder CancerLast Updated:October 2, 2019Recruiting
5
Durvalumab for Advanced Hepatocellular Carcinoma in Patients With Active Chronic Hepatitis B Virus Infection
Condition(s):Advanced Hepatocellular CarcinomaLast Updated:August 4, 2020Not yet recruiting
6
Trial Evaluating the Tolerance and Safety of Durvalumab – RT Combination for Treatment in SCCHN
Condition(s):HNSCCLast Updated:April 9, 2020Recruiting
7
A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTION
Condition(s):Non Small Cell Lung Cancer; Renal Cell CarcinomaLast Updated:August 14, 2020Not yet recruiting
8
Spanish Real World Data on Patients Treated With Durvalumab After Chemoradiotherapy.
Condition(s):Small Cell Lung Cancer (SCLC)Last Updated:August 21, 2020Recruiting
9
Durvalumab in Solid Tumors
Condition(s):HIV; CancerLast Updated:November 13, 2019Active, not recruiting
10
Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC
Condition(s):Stage III Non-small Cell Lung Cancer; UnresectableLast Updated:August 3, 2020Active, not recruiting